Facebook
Twitter
LinkedIn
ForwardAdvancements in Urology, an AUA/JUA Symposium (2017)
Urologists and those practicing urology need a thorough knowledge of the most recent developments and techniques in urology to ensure the highest standards of patient care and safety. This program is designed to inform on the technical aspects of the surgical management and treatment of urologic cancer, focusing on the diagnosis, treatment, clinical advances, and controversies in localized and advanced urologic cancers; stress urinary incontinence (SUI); management and treatment of urolithiasis; urethral stricture disease; and benign hyperplasia.
Target Audience
- Urologists
Learning Objectives
Upon completion of this course, attendees will be able to:
Bladder and Upper Tract Urothelial Carcinoma
- Discuss the management of the patient with carcinoma-in-situ of the bladder.
- Identify technological advances that facilitate the endoscopic management of upper tract urothelial carcinoma.
- Identify patients with advanced bladder cancer who are candidates for neoadjuvant or adjuvant chemotherapy.
- Discuss advances in the management of metastatic urothelial carcinoma and the role of immune checkpoint inhibitors.
Renal Cancer
- Define differences in technology and outcomes for thermo-ablative approaches to renal cell cancer.
- Identify key surgical steps in robotic partial nephrectomy.
- Detail evidence-based guidelines for the management of small renal masses.
- Detail the alternatives for medical therapy of advanced renal cell cancer.
- Discuss the effects of immune system checkpoint inhibitors on the immunosuppressive activity of tumor cells and appraise clinical investigations into the efficacy of immune system checkpoint inhibitors in the treatment of renal cancer.
- Discuss indication and timing of cytoreductive nephrectomy and metastatectomy in advanced renal cell carcinoma.
Prostate Cancer
- Review the use of genomic biomarkers in the prognostication of prostate cancer outcome and prediction of therapeutic response.
- Detail the application of genomics to the risk stratification of the prostate cancer patient.
- Express how to optimize prostate biopsy both from patient experience and cancer detection standpoints.
- Detail the alternatives for medical therapy of prostate cancer.
- Describe new therapeutic agents for the management of castration resistant prostate cancer (CRPC) and outline a coherent strategy for their use.
Urolithiasis
- Identify surgical tips for flexible ureteroscopy to optimize outcomes and minimize complications.
- Identify treatment strategies to optimize outcomes and minimize complications with extracorporeal shockwave lithotripsy.
- Distinguish the latest techniques, tips and innovations in percutaneous renal surgery, ureteroscopy and shock wave lithotripsy (SWL).
- Detail evidence-based guidelines for medical and dietary kidney stone prevention.
- Detail the surgical steps for endoscopic-guided percutaneous renal access for stone extraction.
Urinary Incontinence and Prolapse Management
- Identify the treatments for refractory overactive bladder (OAB) including indications and outcomes.
- Discuss conservative measures to treat urinary incontinence and pelvic organ prolapse in women.
- Describe common surgical treatments for urinary incontinence and pelvic organ prolapse in women including indications and outcomes.
- Compare conservative and surgical treatment options for men with post prostatectomy incontinence.
BPH & LUTS
- Describe current guidelines for the assessment and treatment of LUTS in men.
- Differentiate the new and evolving technology and techniques for minimally invasive treatment of BPH.
Trauma and Reconstruction
- Stratify patient management for urethral strictures.
- Define the diagnostic and therapeutic algorithms for management of the patient with blunt and penetrating urologic trauma.
- Define specific techniques for urethral stricture reconstruction and detail their indications.
Thursday, January 12, 2017
7 – 8 a.m. Continental Breakfast & Registration
8 – 8:05 a.m. Opening Remarks - Richard K. Babayan, MD
Bladder and Upper Tract Urothelial Carcinoma
Moderators: Chikara Ohyama, MD, PhD and Sia Daneshmand, MD
8:05 – 8:20 a.m. Evolving Concept in the Management of CIS - Hiroyuki Nishiyama, MD, PhD
8:20 – 8:40 a.m. How to Manage and Follow Upper Tract Tumors - Andrew Stephenson, MD
8:40 – 9 a.m. Neoadjuvant and Adjuvant Treatment for Bladder Cancer-Indication, Implication, Importance - Hiroshi Kitamura, MD, PhD
9 – 9:20 a.m. Update in the Treatment of Advanced Metastatic UC - Sia Daneshmand, MD
9:20 – 9:45 a.m. Panel Discussion: Case Management for Bladder Cancer
Moderators: Masayuki Nakagawa, MD, PhD and Sia Daneshmand, MD
Discussants: Takahiko Mitsui, MD, PhD; Yoshihisa Matsukawa, MD, PhD; Andrew Stephenson, MD; Sia Daneshmand, MD
9:45 – 10 a.m. Break
Renal Cancer
Moderators: Mototsugu Oya, MD, PhD and Inderbir S. Gill, MD, MCh
10 – 10:20 a.m. Nephron Sparing Surgery for Renal Tumors - Nobuyuki Hinata, MD, PhD
10:20 – 10:40 a.m. Surgical Management for IVC Thrombus and Its Outcome - Inderbir S. Gill, MD, MCh
10:40 – 11 a.m. Current Status of Cytoreductive Nephrectomy and Metastatectomy in mRCC Patients - Sia Daneshmand, MD
11 – 11:20 a.m. Update in the Treatment of mRCC, How to Use Immune Checkpoint Blockade - Masatoshi Eto, MD, PhD
11:20 – 11:45 a.m. Panel Discussion: Case Management for Renal Cancer
Moderators: Yoshihiko Tomita, MD, PhD and Inderbir S. Gill, MD, MCh
Discussants: Tomoya Fukawa, MD, PhD; Motohide Uemura, MD, PhD; Inderbir S. Gill, MD, MCh; Sia Daneshmand, MD
11:45 a.m. – 1:00 p.m. Lunch
Friday, January 13, 2017
7 – 8 a.m. Continental Breakfast
Prostate Cancer
Moderators: Shin Egawa, MD, PhD and Inderbir S. Gill, MD, MCh
8 – 8:20 a.m. Update of Prostate Cancer Diagnosis—Biomarkers in Prostate Cancer - Norio Nonomura, MD, PhD
8:20 – 8:40 a.m. Update of Prostate Cancer Diagnosis—Imaging Studies - Andrew Stephenson, MD
8:40 – 9 a.m. Update on Prostate Cancer Biopsy Reporting - Toshiyuki Kamoto, MD, PhD
9 – 9:20 a.m. Update in the Treatment of mCRPC - Sia Daneshmand, MD
9:20 – 9:45 a.m. Panel Discussion: Case Management for Prostate Cancer
Moderators: Isao Hara, MD, PhD and Andrew Stephenson, MD
Discussants: Jun Miki, MD, PhD; Takashi Kobayashi, MD, PhD; Inderbir S. Gill, MD, MCh; Andrew Stephenson, MD
9:45 – 10 a.m. Break
Urolithiasis
Moderators: Katsuhito Miyazawa, MD, PhD and Manoj Monga, MD, FACS
10 – 10:20 a.m. Unresolved Issues in Stone Management—An Overview - Richard K. Babayan, MD
10:20 – 10:40 a.m. Endoscopic Treatment of Renal Stones— Percutaneous Nephrolithotomy - Manoj Monga, MD, FACS
10:40 – 11 a.m. Endoscopic Treatment of Renal Stones—FTUL - Junichi Matsuzaki, MD, PhD
11 – 11:20 a.m. Medical and Dietary Stone Prevention - Taro Iguchi, MD, PhD
11:20 – 11:45 a.m. Panel Discussion: Case Management for Urinary Stones
Moderators: Shizuka Iida, MD, PhD and Richard K. Babayan, MD
Discussants: Atsushi Okada, MD, PhD; Taro Iguchi, MD, PhD; Kyoko Sakamoto, MD; Manoj Monga, MD, FACS
11:45 a.m. – 1:00 p.m. Lunch
Saturday, January 14, 2017
7 – 8 a.m. Continental Breakfast
Urinary Incontinence & Prolapse Management
Moderators: Hirotaka Asakura, MD, PhD and Larissa Rodriquez, MD
8 – 8:20 a.m. Refractory OAB - Hidehiro Kakizaki, MD, PhD
8:20 – 8:40 a.m. Conservative Managements for Incontinence and Prolapse - Michael E. Albo, MD
8:40 – 9 a.m. Surgical Management for Incontinence and Prolapse - Momokazu Gotoh, MD
9 – 9:20 a.m. Treatment for Post-operative Incontinence - Michael E. Albo, MD
9:20 – 9:45 a.m. Panel Discussion: Case Management for Urinary Incontinence & Prolapse
Moderators: Hikaru Tomoe, MD, PhD and Michael E. Albo, MD
Discussants: Manami Kinjo, MD, PhD; Yasukuni Yoshimura, MD, PhD; Larissa Rodriquez, MD
9:45 – 10 a.m. Break
BPH & LUTS
Moderators: Naoya Masumori, MD, PhD and Richard K. Babayan, MD
10 – 10:20 a.m. Guidelines for Male LUTS - Tomonori Yamanishi, MD, PhD
10:20 – 10:40 a.m. Evolving Techniques of Minimally Invasive Surgery in the Treatment of BPH - Steven A. Kaplan, MD
10:40 – 11 a.m. Panel Discussion: Case Management for BPH & LUTS
Moderators: Yoshiyuki Kojima, MD, PhD and Richard K. Babayan, MD
Discussants: Ryosuke Takahashi, MD, PhD; Yasuhito Funahashi, MD, PhD; Steven A. Kaplan, MD; Richard K. Babayan, MD
Trauma & Reconstruction
Moderators: Hirotsugu Uemura, MD, PhD and Allen F. Morey, MD, FACS
11 – 11:20 a.m. Reconstruction of Urethral Strictures 2016 - Allen F. Morey, MD FACS
11:20 – 11:40 a.m. Update in the Management of Kidney and Ureteral Injuries - Yosuke Nakajima, MD, PhD
11:40 a.m. – Noon Panel Discussion: Case Management for Trauma & Reconstruction
Moderators: Makoto Sumitomo, MD, PhD and Allen F. Morey, MD, FACS
Discussants: Yosuke Nakajima, MD, PhD; Hirotsugu Uemura, MD, PhD
Noon Closing Remarks - Masato Fujisawa, MD, PhD
There's something electric about being in the middle of it all. Hard Rock Hotel San Diego puts you in the limelight with chic accommodations just steps from downtown and the famed nightlife of the Gaslamp Quarter. Whether you're here to catch a game at PETCO Park (located just one block away) or attend a corporate event at the San Diego Convention Center (right across the street), we'll take you there.
But we're so much more than a great location. Our award-winning service and stunning event venues amp up any occasion, with group packages that make your attendees all VIPs. You can live it up without ever leaving the hotel — try a jam session in your suite with our complimentary Sound of Your Stay® service, or mouthwatering sushi at world-famous Nobu, and rooftop cocktails at Float rooftop lounge or 207 bar. Indulge your body at our full-service Rock Spa, or free your mind with a stress-crushing workout in our 24-hour fitness center.
Check In: 4:00 PM
Check Out: 11:00 AM
Parking: Valet Parking is available at the Hard Rock for $47.00 Overnight and $20.00 Day of Event Only, plus tax. Prices are subject to change.
Transportation: San Diego International Airport is located 3 miles from the hotel, approximately a 15 minute drive. Average Cab Fare is $16.00
Accreditation
The American Urological Association Education and Research, Inc. (AUAER) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation
The American Urological Association Education & Research, Inc. designates this live activity for a maximum of 10.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Other Learners
The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
Evidence Based Content
It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA Disclosure Policy
All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
Resolution of Identified Conflict of Interest
All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:
- Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
- Limit content to evidence with no recommendations
- Introduction of a debate format with an unbiased moderator (point-counterpoint)
- Inclusion of moderated panel discussion
- Publication of a parallel or rebuttal article for an article that is felt to be biased
- Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
- Divestiture of the relationship by faculty
Off-label or Unapproved Use of Drugs or Devices
It is the policy of the AUA to require the disclosure of all references to off-label or unapproved uses of drugs or devices prior to the presentation of educational content. The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
Available Credit
- 10.75 AMA PRA Category 1 Credit™
- 10.75 Non-Physician Participation